Year in Review: Onwards & Upwards
Thank you for your continued support of Resverlogix over the last year! Drug development can be a rocky road but we are still going strong. This past year has been a whirlwind of events as we have had...
View ArticleNew Analyst Coverage on Resverlogix
A new analyst report has been published covering the cost benefits of RVX-208 and discussing our single epigenetic target with effects on multiple synchronized biological pathways. Marcel Wijma, chief...
View ArticleClik here to view.
Dr. Norman Wong presents at EAS Congress, Glasgow, Scotland
Dr. Norman CW Wong, CSO of Resverlogix presented data on RVX-208 at the European Atherosclerosis Society (EAS) annual meeting in an oral abstract entitled: “RVX-208 a selective bromodomain...
View ArticleNew Analyst Report: Analysis of the Science Behind RVX-208
Published today on Seeking Alpha, Bjarke Krysel Christensen authored a report on Resverlogix entitled: “Analysis of the Science Behind RVX-208”.
View ArticleResverlogix Presents at the ATVB Scientific Sessions in San Francisco, CA
Reporting from San Francisco, CA: Today, Resverlogix’s Chief Scientific Officer Dr. Norman CW Wong is presenting data on RVX-208 at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)...
View ArticleResverlogix presents at the 2015 EASD annual meeting in Stockholm, Sweden
Today Dr. Norman Wong, Chief Scientific Officer of Resverlogix presented an oral abstract entitled ‘RVX-208 acts via an epigenetic mechanism to lower major adverse cardiovascular events (MACE) in...
View ArticleResverlogix’s Poster Presentation and eVideo from the EASD
On September 14, 2016, Dr. Norman Wong, Chief Scientific Officer of Resverlogix Corp. presented an abstract entitled “Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular...
View ArticleClik here to view.
ESC Congress 2016 Epigenetics Symposium: Meeting Highlights, Videos & Slides
Resverlogix supported a PACE-CME educational symposium on Epigenetics at the European Society of Cardiology (ESC) Congress 2016, titled: “A Novel Approach for High CV Risk Patients with Diabetes: The...
View Article
